Uploaded August 2026 | Updated September 2026, 2 weeks ago
"Drink Your Cannabinoids: How It Changes Cannabis Research and Patient Care" panel discussion at CannMed 2026, covering cannabis emulsion technology, cannabinoid bioavailability, and precision dosing.
Sponsored by phytoRX
Cannabis emulsion technology is unlocking a new era of precision dosing, faster onset, improved bioavailability, and research-grade delivery systems, reshaping both patient care and clinical cannabis research.
This panel brings together leading clinicians, researchers, and innovators to explore how emulsion-based cannabinoids are improving outcomes in oncology, geriatrics, and pharmaceutical-grade clinical trials, including real-world patient applications and IND-aligned research studies.
Panelists discuss how emulsions enable more consistent dosing, higher patient adherence, better study reproducibility, and more credible pathways for FDA-aligned research, including ongoing work in glioblastoma, cancer symptom management, senior care, and institutional research partnerships.
Attendees will gain a forward-looking view of why emulsions may become the gold standard delivery method for both cannabis medicine and next-generation cannabinoid drug development.
Panelists:
Harold Han, PhD (Moderator), Founder, phytoRX
Dr. Jean Talleyrand, Cannabis Clinician & Medical Director
Dr. Anthony Ferrari, Co-Founder & Director of Science, Sym Sciences
Justin Kander, Cancer Cannabis Specialist & Author
Michael Flemmens, Scientist, SōRSE Technology
Maureen Smyth, BSN, RN, Founder, Cannabis Public School
This presentation was given at the CannMed 2026 Innovation & Collaboration Summit, held June 15-18 at the Hyatt Regency Lake Tahoe Resort. Visit cannmedevents.com to learn more.
"Drink Your Cannabinoids: How It Changes Cannabis Research and Patient Care" panel discussion at CannMed 2026, covering cannabis emulsion technology, cannabinoid bioavailability, and precision dosing.
Sponsored by phytoRX
Cannabis emulsion technology is unlocking a new era of precision dosing, faster onset, improved bioavailability, and research-grade delivery systems, reshaping both patient care and clinical cannabis research.
This panel brings together leading clinicians, researchers, and innovators to explore how emulsion-based cannabinoids are improving outcomes in oncology, geriatrics, and pharmaceutical-grade clinical trials, including real-world patient applications and IND-aligned research studies.
Panelists discuss how emulsions enable more consistent dosing, higher patient adherence, better study reproducibility, and more credible pathways for FDA-aligned research, including ongoing work in glioblastoma, cancer symptom management, senior care, and institutional research partnerships.
Attendees will gain a forward-looking view of why emulsions may become the gold standard delivery method for both cannabis medicine and next-generation cannabinoid drug development.
Panelists:
Harold Han, PhD (Moderator), Founder, phytoRX
Dr. Jean Talleyrand, Cannabis Clinician & Medical Director
Dr. Anthony Ferrari, Co-Founder & Director of Science, Sym Sciences
Justin Kander, Cancer Cannabis Specialist & Author
Michael Flemmens, Scientist, SōRSE Technology
Maureen Smyth, BSN, RN, Founder, Cannabis Public School
This presentation was given at the CannMed 2026 Innovation & Collaboration Summit, held June 15-18 at the Hyatt Regency Lake Tahoe Resort. Visit cannmedevents.com to learn more.
